Transgene Biotek Limited (TRABI.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-207.0%

-₹2.61

vs ₹2.44 price

Levered DCF

-₹2.28

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

—

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-9×	-38.78×	-89.11×	-12.42×	-7.16×	-7.11×	-6.77×	-8.46×
P/B	1.78×	2.61×	-8.5×	6.54×	4.28×	3.34×	2.27×	1.7×
P/S	70.44×	100.57×	248.67×	1,349.38×	857.38×	438.4×	20,789.39×	1,042.69×
EV / EBITDA	-58.79×	-119.01×	-166.87×	-99.69×	-347.33×	-335.05×	-123.59×	61.56×
Gross margin	-296.7%	100.0%	-72.0%	-20.4%	153.3%	64.1%	-313.6%	52.5%
Operating margin	-351.6%	-466.6%	-301.8%	-10897.1%	-11982.0%	-6154.6%	-300960.4%	-14838.3%
Net margin	-782.6%	-259.3%	-279.1%	-10907.9%	-11998.4%	-6154.3%	-306601.7%	-12334.2%
Current ratio	0.08×	0.1×	0.1×	0.1×	0.08×	0.05×	0.05×	0.05×
Debt / equity	2.05×	1.45×	-2.04×	1.15×	0.69×	0.51×	0.32×	0.21×
Interest coverage	-0.7×	-5.01×	-5.08×	-9.63×	-45.34×	-38.51×	-28.26×	-40.53×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-19.7%	-6.7%	9.5%	-52.9%	-59.9%	-46.9%	-33.6%	-20.2%
Return on invested capital	-0.5%	-0.9%	-0.5%	-4.3%	-7.2%	-7.0%	-6.8%	-6.3%
Return on assets	-1.2%	-0.5%	-0.5%	-4.2%	-7.1%	-6.7%	-6.6%	-5.0%
Free cash flow yield	-20.1%	-1.9%	0.0%	-0.0%	0.1%	-0.0%	0.2%	-2.4%
Earnings yield	-11.1%	-2.6%	-1.1%	-8.1%	-14.0%	-14.0%	-14.7%	-11.8%
Enterprise value	₹319.5M	₹404.5M	₹724.1M	₹874.4M	₹863.3M	₹856.6M	₹846.3M	₹833.6M
Net debt / EBITDA	-31.42×	-41.88×	-32.25×	-14.95×	-48.27×	-44.3×	-15.04×	6.67×
Cash conversion cycle (days)	-0	-374	-133	-1,017	890	-1,296	-7,559	-2,797